Uncategorized Archives - Page 35 of 249

TuesdaySep 06, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability

Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffness Although hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under control A Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effects Lexaria’s DehydraTECH-CBD may…

WednesdayAug 31, 2022 12:15 pm

REZYFi, Inc. Is ‘One to Watch’

REZYFi Lending sees higher margin lending opportunities as well as significant market opportunity to provide the growing and underserved cannabis industry with financial services ResMac forecasts $285 million in retail loan origination in 2023 and foresees strong growth opportunities ResMac is on pace to originate $250 million in wholesale loan business in 2023, with its year-over-year credit facility increase expected to jump more than 300% The company’s management team has more than 40 years’ experience in the mortgage and lending industry REZYFi expects to operate nationwide by the end of 2022; it currently operates in 34 states REZYFi is a…

TuesdayAug 30, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose…

MondayAug 29, 2022 9:00 am

AROYA Crop Steering Expertise and Technology Provides Data-Driven Insights, Automation and Competitive Advantage for Successful Harvests

For cannabis operators, crop steering directs how their plants grow as well as their literal shape. Knowing how and when to manipulate light, climate and irrigation – the three foundational components of crop steering – is essential to balancing high yields and high quality. Why do successful growers – from small craft farmers to the largest multistate operators – use data-driven and automated crop steering solutions? Because even the slightest adjustments to any number of factors can have huge effects on grows. Data is the lifeblood of a plant growers, providing the intelligence to track how and when plants change…

FridayAug 26, 2022 11:15 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program As a follow-up to recent coverage…

FridayAug 19, 2022 10:30 am

NECANN 3rd Annual New Jersey Cannabis Convention Brings the East Coast Cannabis Community under One Roof

The NECANN Conference has evolved into the largest conference on the East Coast, attracting cannabis cultivators, traders, regulators, lawmakers, and enthusiasts, from the East Coast and beyond. The 3rd annual New Jersey Cannabis Convention is being held from September 9-10, 2022, in Atlantic City, New Jersey. This is a well-curated event organized by a highly talented team of professionals with desired expertise and experience. They keep in mind the needs and requirements of the cannabis community and bring together investors, young and veteran cannabis and hemp traders, as well as researchers and lawmakers, all in a common forum. After fighting…

FridayAug 19, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if…

ThursdayAug 18, 2022 4:20 pm

420 with CNW — State Data Says Michigan Cannabis Sales Broke Monthly Record in July

The Cannabis Regulatory Agency in the state of Michigan recently published data showing that the state set a new record for cannabis sales last month. The state reached almost $210 million in total marijuana sales, recording more than $188 million in adult-use cannabis purchases and more than $21 million in medical marijuana sales in the month of July. This total is almost $15 million higher than the previous record the state set earlier in the year. The majority of the cannabis purchases for both recreational and medical use were for flower products, with vape cartridges coming in second. The data…

TuesdayAug 16, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn In…

FridayAug 12, 2022 11:15 am

The New York Cannabis and Hemp Convention to Boost the Growing Local Markets

Businesses, entrepreneurs, advocates, patients, investors, educators, and consumers, are invited to attend the NECANN Convention, a physical event being held in Albany, New York on August 26-27, 2022. NECANN has been producing popular and influential events to local communities throughout the northeast and beyond since 2014, shaping the developing cannabis economy by creating an important hub of resources and communication focused on local markets. NECANN events attract a huge number of hemp, MMJ, and cannabis industry professionals in the Northeast, and represent a home base for the New England cannabis industry. The New England Cannabis Convention offers a wonderful opportunity…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized